Platform Specialty Products Buys Arysta for $3.51 Billion

300x199platform

On the heels of its announcement to buy Chemtura AgroSolutions in April and Agriphar in August, U.S.-based Platform Specialty Products Corp. has agreed to purchase Arysta LifeScience for $3.51 billion. Arysta has 3,600 product registrations in more than 100 countries and revenues of $1.5 billion in 2013.

Advertisement

Just as the company said with its previous acquisitions, Platform says Arysta is in line with the company’s “asset-lite, high-touch” business model, which means that Platform likes being a post-patent company that doesn’t originate active ingredients. Instead it plans to capitalize on highly differentiated, specialized and localized products and formulations driven by Arysta’s 1,300 sales and marketing professionals.

Platform’s businesses generated $746 million in 2013, so the Arysta deal will more than double company revenues. Company founder and Chairman Martin Franklin hints that it is still looking for other deals in crop protection.

“This is a watershed event for Platform. Over the past twelve months we have demonstrated significant progress and exercised tremendous discipline as we executed against our build-up strategy,” Franklins said in a press release. “Through the acquisitions of Arysta, CAS, and Agriphar we have established a leading position within an attractive asset-lite, high-touch specialty chemicals vertical. As we work to accelerate the organic growth within these businesses, we remain opportunistic on the acquisition front and will look to strategically expand our portfolio across other attractive, niche verticals. The management teams we have assembled through our acquisitions provide us with some of the best talent in the industry, and I am confident that by working together, each of our businesses will thrive and create increasing value for our shareholders.”

Top Articles
ADAMA Reports Fourth Quarter and Full Year 2023 Results

Read the full announcement on Platform’s website.

 

Hide picture